News

Business Wire1mon
ViroCell Manufactured a GMP Lentiviral Vector for UCL to Accelerate Research Into Prevention of Relapse in Childhood Blood Cancer
and UCL’s world-leading research capabilities are supported by ViroCell’s delivery of a high quality, high yield lentiviral vector to advance UCL’s Phase I CARPALL (cohort 4) clinical trial ...
PharmiWeb26d
ViroCell manufactured a GMP lentiviral vector for…
UCL leveraged ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia London, UK and New York, US, 17 ...
Morningstar1mon
ViroCell Manufactured a GMP Lentiviral Vector for UCL to Accelerate Research Into Prevention of Relapse in Childhood Blood Cancer
UCL leveraged ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia ViroCell Biologics ...